BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook

On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) unveiled fresh clinical data for its lead KRASG12C inhibitor, BBO-8520. Leveraging this opportunity, the company decided to narrow its focus on BBO-8520 in combination with checkpoint inhibitors for patients with previously treated lung cancer, alongside ongoing combination studies for its two earlier-stage assets, BBO-11818 and BBO-10203, targeting other KRAS-mutant tumors.

This strategic shift reflects BridgeBio's belief in where its investments can make the most impact. A key figure from the September 8 release is a 75% objective response rate when BBO-8520 was combined with pembrolizumab in patients whose lung cancer had progressed on a prior G12C inhibitor, with a 53% response rate across all tested doses.

Lung cancer patients with the KRAS G12C mutation, estimated to be around 21,000 in the US in 2026, have no approved targeted therapy once a first G12C drug stops working, and BridgeBio anticipates this pool will expand as newer inhibitors move earlier into treatment. BBO-8520 monotherapy also showed promise in patients who had never taken a G12C inhibitor, with a 63% response rate, and no patients experienced grade 3 liver enzyme elevations, a common side effect in this class of drugs.

At June 30, the company had $344.1 million in cash, which is expected to fund operations until 2028, allowing management to concentrate capital on promising combination strategies, including internal trials involving BBO-11818 and BBO-10203. However, the early-stage data is still pending, with the most validating data for the strategic pivot - the expanded 8520-pembrolizumab dataset and combination results in colorectal and pancreatic cancer - not expected until mid-2027.

Currently, short interest stands at 21.69% of the float, indicating organized skepticism about the early-phase response rates' durability in larger trials. While BridgeBio is betting on a 75% response rate in a patient population with no other options, the company is also burning cash at a faster rate than a year ago. For potential investors, this presents a dual risk-reward scenario, requiring confirmation of early-phase results by larger trials to validate the company's strategic shift.